Tabula Rasa HealthCare Inc (NASDAQ:TRHC) President Orsula V. Knowlton sold 8,000 shares of the stock in a transaction on Thursday, July 18th. The shares were sold at an average price of $54.85, for a total value of $438,800.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Tabula Rasa HealthCare stock opened at $54.78 on Monday. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.80 and a quick ratio of 1.73. The firm has a market capitalization of $1.20 billion, a P/E ratio of 161.12 and a beta of 1.62. Tabula Rasa HealthCare Inc has a one year low of $40.86 and a one year high of $91.16. The stock’s fifty day simple moving average is $49.52.
Tabula Rasa HealthCare (NASDAQ:TRHC) last posted its earnings results on Wednesday, May 8th. The company reported ($0.14) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.14). The firm had revenue of $60.96 million for the quarter, compared to the consensus estimate of $59.24 million. Tabula Rasa HealthCare had a negative net margin of 18.15% and a positive return on equity of 4.22%. Equities research analysts forecast that Tabula Rasa HealthCare Inc will post -0.55 EPS for the current year.
Several analysts recently issued reports on TRHC shares. ValuEngine upgraded Zillow Group from a “hold” rating to a “buy” rating in a report on Thursday, July 11th. Guggenheim started coverage on Patterson Companies in a report on Wednesday, April 17th. They set a “neutral” rating and a $23.00 price objective for the company. TheStreet lowered Twin Disc from a “b-” rating to a “c+” rating in a report on Tuesday, June 11th. Cantor Fitzgerald started coverage on CytomX Therapeutics in a report on Monday, May 13th. They set an “overweight” rating and a $21.00 price objective for the company. Finally, Piper Jaffray Companies increased their price objective on Beigene to $180.00 and gave the stock an “overweight” rating in a report on Thursday, May 9th. Three research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $82.12.
Institutional investors have recently bought and sold shares of the business. First Mercantile Trust Co. increased its position in Tabula Rasa HealthCare by 64.5% during the first quarter. First Mercantile Trust Co. now owns 995 shares of the company’s stock worth $56,000 after buying an additional 390 shares during the last quarter. South Dakota Investment Council acquired a new position in Tabula Rasa HealthCare during the first quarter worth $141,000. Belpointe Asset Management LLC acquired a new stake in shares of Tabula Rasa HealthCare in the first quarter valued at about $172,000. LS Investment Advisors LLC grew its position in shares of Tabula Rasa HealthCare by 11.2% in the first quarter. LS Investment Advisors LLC now owns 3,129 shares of the company’s stock valued at $177,000 after purchasing an additional 316 shares during the last quarter. Finally, RMB Capital Management LLC acquired a new stake in shares of Tabula Rasa HealthCare in the fourth quarter valued at about $220,000. 85.92% of the stock is currently owned by hedge funds and other institutional investors.
About Tabula Rasa HealthCare
Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the field of medication safety in the United States. The company's proprietary Medication Risk Mitigation Matrix delivers a multi-drug review, which identifies medication-related risks. Its cloud-based software applications include EireneRx, a medication decision-support and e-prescribing platform to access patients' medication-related information; and MedWise that provides medication decision support components for clients seeking to manage their medication risk and improve medication outcomes, and patient relationships by enhancing their existing systems.
Further Reading: Neutral Rating
Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.